Brian Druker

95.6k total citations · 23 hit papers
607 papers, 54.8k citations indexed

About

Brian Druker is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Brian Druker has authored 607 papers receiving a total of 54.8k indexed citations (citations by other indexed papers that have themselves been cited), including 438 papers in Hematology, 328 papers in Genetics and 167 papers in Rheumatology. Recurrent topics in Brian Druker's work include Chronic Myeloid Leukemia Treatments (353 papers), Chronic Lymphocytic Leukemia Research (272 papers) and Eosinophilic Disorders and Syndromes (165 papers). Brian Druker is often cited by papers focused on Chronic Myeloid Leukemia Treatments (353 papers), Chronic Lymphocytic Leukemia Research (272 papers) and Eosinophilic Disorders and Syndromes (165 papers). Brian Druker collaborates with scholars based in United States, Switzerland and Germany. Brian Druker's co-authors include Elisabeth Buchdunger, Nicholas Lydon, Michael W. Deininger, Renaud Capdeville, Moshe Talpaz, Charles L. Sawyers, Debra Resta, Hagop M. Kantarjian, J. Ford and Sayuri Ohno-Jones and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Brian Druker

587 papers receiving 53.3k citations

Hit Papers

Efficacy and Safety of a Specific Inhibitor of the BCR-AB... 1996 2026 2006 2016 2001 1996 2001 2003 2001 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
    2001 3.8k citations Brian Druker, Moshe Talpaz et al. profile →
  2. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
    1996 2.8k citations Brian Druker et al. profile →
  3. Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
    2001 2.1k citations Brian Druker, Charles L. Sawyers et al. profile →
  4. Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
    2003 1.7k citations Michael C. Heinrich, Christopher L. Corless et al. profile →
  5. Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor
    2001 1.5k citations Brian Druker et al. profile →
  6. Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
    2002 1.5k citations Charles L. Sawyers, Andreas Hochhaus et al. profile →
  7. Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors
    2000 1.0k citations Brian Druker et al. profile →
  8. The development of imatinib as a therapeutic agent for chronic myeloid leukemia
    2004 960 citations Michael W. Deininger, Brian Druker et al. Blood profile →
  9. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
    1996 878 citations Brian Druker et al. PubMed profile →
  10. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
    2000 831 citations Michael C. Heinrich, Brian Druker et al. Blood profile →
  11. In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants
    2005 812 citations Thomas O’Hare, Denise K. Walters et al. Cancer Research profile →
  12. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
    2017 797 citations Andreas Hochhaus, Richard A. Larson et al. profile →
  13. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
    2002 675 citations Andreas Hochhaus, Paul La Rosée et al. profile →
  14. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
    2000 645 citations Brian Druker et al. profile →
  15. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
    2009 627 citations Andreas Hochhaus, François Guilhot et al. profile →
  16. CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
    2010 588 citations Jeffrey Tyner, Marc Loriaux et al. Blood profile →
  17. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
    2010 586 citations Amie S. Corbin, Anupriya Agarwal et al. profile →
  18. Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
    2012 527 citations Jörge E. Cortes, Hagop M. Kantarjian et al. profile →
  19. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
    2008 491 citations Richard A. Larson, Brian Druker et al. Blood profile →
  20. Translation of the Philadelphia chromosome into therapy for CML
    2008 476 citations Brian Druker Blood profile →
  21. International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.
    2009 444 citations Michael W. Deininger, Stephen G. O’Brien et al. Blood profile →
  22. OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML
    2013 356 citations Julia E. Maxson, Jason Gotlib et al. profile →
  23. Response and Resistance to BCR-ABL1-Targeted Therapies
    2020 308 citations Theodore P. Braun, Christopher A. Eide et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brian Druker United States 106 30.5k 21.7k 17.1k 13.5k 10.9k 607 54.8k
Moshe Talpaz United States 98 29.2k 1.0× 22.8k 1.1× 11.0k 0.6× 13.1k 1.0× 8.7k 0.8× 778 44.8k
Charles L. Sawyers United States 99 15.8k 0.5× 11.6k 0.5× 24.8k 1.4× 6.9k 0.5× 12.3k 1.1× 266 53.4k
Francis J. Giles United States 105 20.4k 0.7× 15.8k 0.7× 15.0k 0.9× 6.3k 0.5× 9.3k 0.8× 786 41.9k
Andreas Hochhaus Germany 87 30.1k 1.0× 24.0k 1.1× 6.1k 0.4× 15.6k 1.2× 7.3k 0.7× 839 40.0k
James D. Griffin United States 95 12.4k 0.4× 6.3k 0.3× 12.8k 0.7× 2.7k 0.2× 7.4k 0.7× 354 29.7k
Guillermo Garcia‐Manero United States 106 30.6k 1.0× 14.7k 0.7× 17.8k 1.0× 4.4k 0.3× 7.5k 0.7× 1.5k 44.1k
William G. Wierda United States 88 11.0k 0.4× 18.2k 0.8× 8.5k 0.5× 1.4k 0.1× 8.1k 0.7× 829 31.7k
Razelle Kurzrock United States 119 6.9k 0.2× 6.8k 0.3× 21.0k 1.2× 2.9k 0.2× 24.9k 2.3× 1.2k 60.4k
Clara D. Bloomfield United States 91 28.5k 0.9× 12.1k 0.6× 17.7k 1.0× 2.1k 0.2× 6.6k 0.6× 406 42.9k
Deborah A. Thomas United States 80 12.3k 0.4× 10.2k 0.5× 6.3k 0.4× 2.6k 0.2× 4.9k 0.5× 451 23.2k

Countries citing papers authored by Brian Druker

Since Specialization
Citations

This map shows the geographic impact of Brian Druker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Druker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Druker more than expected).

Fields of papers citing papers by Brian Druker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Druker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Druker. The network helps show where Brian Druker may publish in the future.

Co-authorship network of co-authors of Brian Druker

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Druker. A scholar is included among the top collaborators of Brian Druker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Druker. Brian Druker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Coleman, Daniel J., Joseph Estabrook, Emek Demir, et al.. (2023). Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia. Molecular Cancer Research. 21(7). 631–647. 5 indexed citations
2.
Yenerall, Paul, Rahul K. Kollipara, Michael Peyton, et al.. (2021). Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations. Cancer Research. 81(18). 4685–4695. 6 indexed citations
3.
Leonard, Jessica, Yoko Kosaka, Dorian LaTocha, et al.. (2020). Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL. Blood. 137(7). 939–944. 17 indexed citations
4.
Burslem, George M., Anna Reister Schultz, Daniel P. Bondeson, et al.. (2019). Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation. Cancer Research. 79(18). 4744–4753. 165 indexed citations
5.
Maxson, Julia E., Melissa L. Abel, Jinhua Wang, et al.. (2016). Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis. Cancer Research. 76(1). 127–138. 26 indexed citations
6.
Traer, Elie, Jacqueline Martinez, Nathalie Javidi‐Sharifi, et al.. (2016). FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Cancer Research. 76(22). 6471–6482. 96 indexed citations
7.
Drilon, Alexander, Romel Somwar, Jacob P. Wagner, et al.. (2015). A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1 -Rearranged Lung Cancer. Clinical Cancer Research. 22(10). 2351–2358. 128 indexed citations
8.
Agarwal, Anupriya, Raffaella Pippa, Christopher A. Eide, et al.. (2014). Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia. Clinical Cancer Research. 20(8). 2092–2103. 103 indexed citations
9.
O’Hare, Thomas, Christopher A. Eide, Anupriya Agarwal, et al.. (2013). Threshold Levels of ABL Tyrosine Kinase Inhibitors Retained in Chronic Myeloid Leukemia Cells Determine Their Commitment to Apoptosis. Cancer Research. 73(11). 3356–3370. 23 indexed citations
10.
Corbin, Amie S., Thomas O’Hare, Zhimin Gu, et al.. (2013). KIT Signaling Governs Differential Sensitivity of Mature and Primitive CML Progenitors to Tyrosine Kinase Inhibitors. Cancer Research. 73(18). 5775–5786. 17 indexed citations
11.
Tyner, Jeffrey, Armand Bankhead, Guang Fan, et al.. (2012). Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening. Cancer Research. 73(1). 285–296. 100 indexed citations
12.
Eide, Christopher A., Lauren T. Adrian, Jeffrey Tyner, et al.. (2011). The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile. Cancer Research. 71(9). 3189–3195. 77 indexed citations
13.
Larson, Richard A., Brian Druker, François Guilhot, et al.. (2008). Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 111(8). 4022–4028. 491 indexed citations breakdown →
14.
15.
Rosée, Paul La, Taiping Jia, Nicolai Härtel, et al.. (2006). Antileukemic Activity of Lysophosphatidic Acid Acyltransferase-β Inhibitor CT32228 in Chronic Myelogenous Leukemia Sensitive and Resistant to Imatinib. Clinical Cancer Research. 12(21). 6540–6546. 23 indexed citations
16.
Bumm, Thomas G.P., Collin Elsea, Amie S. Corbin, et al.. (2006). Characterization of Murine JAK2V617F-Positive Myeloproliferative Disease. Cancer Research. 66(23). 11156–11165. 151 indexed citations
17.
O’Hare, Thomas, Denise K. Walters, Eric P. Stoffregen, et al.. (2005). In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants. Cancer Research. 65(11). 4500–4505. 812 indexed citations breakdown →
18.
Heinrich, Michael C., Charles D. Blanke, Christopher L. Corless, & Brian Druker. (2003). PDGF Receptors as Therapeutic Targets. The Indian Journal of Medical Research. 55(11). 1259–72. 1 indexed citations
19.
Epstein, Richard J., et al.. (1992). Extracellular calcium mimics the actions of platelet-derived growth factor on mouse fibroblasts.. PubMed. 3(3). 157–64. 11 indexed citations
20.
Epstein, Richard J., Brian Druker, Thomas M. Roberts, & Charles D. Stiles. (1992). Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor.. Proceedings of the National Academy of Sciences. 89(21). 10435–10439. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Moshe Talpaz Breakdown of academic impact, for papers by Charles L. Sawyers Breakdown of academic impact, for papers by Francis J. Giles Breakdown of academic impact, for papers by Andreas Hochhaus Breakdown of academic impact, for papers by James D. Griffin Breakdown of academic impact, for papers by Guillermo Garcia‐Manero Breakdown of academic impact, for papers by William G. Wierda Breakdown of academic impact, for papers by Razelle Kurzrock Breakdown of academic impact, for papers by Clara D. Bloomfield Breakdown of academic impact, for papers by Deborah A. Thomas
Rankless by CCL
2026